TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING
The present invention provides advantageous methods and compositions for treating a host having a cancer with dysregulation of the FGFR signaling pathway, which includes administering an effective amount of a selective CDK4/6 inhibitor described herein in combination or alternation with a fibroblast growth factor receptor inhibitor.
1 . A method of treating a human host with a cancer having a dysregulated fibroblast growth factor receptor (FGFR) signaling pathway caused by an FGFR1 aberration comprising administering to the host an effective amount of a short acting cyclin dependent kinase 4/6 (CDK4/6) inhibitor, and administering to the host an effective amount of a selective fibroblast growth factor receptor-tyrosine kinase inhibitor (FGFR-TKI), wherein the CDK4/6 inhibitor is
or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the FGFR1 aberration is an amplification or overexpression.
3 . The method of claim 1 , wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, triple negative breast cancer, osteosarcoma, pilocytic astrocytoma, and glioblastoma.
4 . The method of claim 1 , wherein the selective FGFR-TKI is selected from the group consisting of erdafitinib, pemigatinib, infigratinib, futibatinib, derazantinib, Debio1347, PRN1371, FIIN, 2, GSK3052230, and PD173074.
5 . The method of claim 1 , wherein the CDK4/6 inhibitor is
Form B, wherein Form B is characterized by an XRPD pattern comprising at least two 2theta values selected from 6.5±0.2°, 9.5±0.2°, 14.0±0.2°, 14.4±0.2°, 18.1±0.2°, 19.9±0.2°, and 22.4±0.2°.
6 . The method of claim 1 , wherein the CDK4/6 inhibitor and the FGFR-TKI are administered to the host at least once a day for at least 28 consecutive days.
7 . A method of treating a human host with a cancer having a dysregulated fibroblast growth factor receptor (FGFR) signaling pathway caused by an FGFR2 aberration comprising administering to the host an effective amount of a short acting CDK4/6 inhibitor, and administering to the host an effective amount of a selective FGFR-TKI, wherein the CDK4/6 inhibitor is
or a pharmaceutically acceptable salt thereof.
8 . The method of claim 7 , wherein the cancer is selected from the group consisting of endometrial cancer, non-small cell lung cancer, gastric cancer, intrahepatic cholangiocarcinoma, and thyroid cancer.
9 . The method of claim 7 , wherein the FGFR2 aberration is selected from the group consisting of an amplification and an overexpression.
10 . The method of claim 7 , wherein the selective FGFR-TKI is selected from the group consisting of erdafitinib, pemigatinib, infigratinib, futibatinib, derazantinib, LY287445, Debio1347, PRN1371, alofanib, bemarituzumab, and FIIN-2.
11 . The method of claim 7 , wherein the CDK4/6 inhibitor is
Form B, wherein Form B is characterized by an XRPD pattern comprising at least two 2theta values selected from 6.5±0.2°, 9.5±0.2°, 14.0±0.2°, 14.4±0.2°, 18.1±0.2°, 19.9±0.2°, and 22.4±0.2°.
12 . The method of claim 7 , wherein the CDK4/6 inhibitor and the FGFR-TKI are administered to the host at least once a day for at least 28 consecutive days.
13 . A method of treating a human host with a cancer with a dysregulated fibroblast growth factor receptor (FGFR) signaling pathway caused by an FGFR3 aberration comprising administering to the host an effective amount of a short acting CDK4/6 inhibitor, and administering to the host an effective amount of a selective FGFR-TKI, wherein the CDK4/6 inhibitor is
or a pharmaceutically acceptable salt thereof.
14 . The method of claim 13 , wherein the cancer is selected from the group consisting of glioblastoma, non-small cell lung cancer, cervical cancer, and multiple myeloma.
15 . The method of claim 13 , wherein the FGFR3 aberration is an FGFR3 translocation or fusion.
16 . The method of claim 13 , wherein the selective FGFR-TKI is selected from the group consisting of erdafitinib, pemigatinib, infigratinib, futibatinib, derazantinib, LY287445, Debio1347, PRN1371, MGFR1877S, vofatamab, and FIIN-2.
17 . The method of claim 13 , wherein the CDK4/6 inhibitor is
Form B, wherein Form B is characterized by an XRPD pattern comprising at least two 2theta values selected from 6.5±0.2°, 9.5±0.2°, 14.0±0.2°, 14.4±0.2°, 18.1±0.2°, 19.9±0.2°, and 22.4±0.2°.
18 . The method of claim 13 , wherein the CDK4/6 inhibitor and the FGFR-TKI are administered to the host at least once a day for at least 28 consecutive days.
19 . A method of treating a human host with a cancer having a dysregulated fibroblast growth factor receptor (FGFR) signaling pathway caused by an FGFR4 aberration or FGF aberration wherein the FGFR4 aberration comprising administering to the host an effective amount of a CDK4/6 inhibitor, and administering to the host an effective amount of a selective fibroblast growth factor receptor (FGFR) inhibitor, wherein the CDK4/6 inhibitor is
or a pharmaceutically acceptable salt thereof.
20 . The method of claim 19 , wherein the cancer is selected from the group consisting of hepatocellular carcinoma, rhabdomyosarcoma, endometrial cancer, and ovarian cancer.
21 . The method of claim 19 , wherein the selective FGFR inhibitor is selected from the group consisting of infigratinib, futibatinib, derazantinib, LY287445, INCB062079, BLU9931, H3-6527, fisogatinib, roblitinib, Debio1347, PRN1371, and FIIN-2.
22 . The method of claim 19 , wherein the CDK4/6 inhibitor is
Form B, wherein Form B is characterized by an XRPD pattern comprising at least two 2theta values selected from 6.5±0.2°, 9.5±0.2°, 14.0±0.2°, 14.4±0.2°, 18.1±0.2°, 19.9±0.2°, and 22.4±0.2°.
23 . The method of claim 19 , wherein the CDK4/6 inhibitor and the FGFR-TKI are administered to the host at least once a day for at least 28 consecutive days.